Patients who come across this figure are often piecing together information from research summaries or informal online sources, trying to understand where it fits into the bigger picture
Why This Matters for Providers By understanding the interplay between GLP-1, GIP, amylin, and glucagon, providers can begin to: Design smarter combination protocols Identify patients at risk of plateau or suboptimal response Use available tools (like pramlintide, SLM+, lifestyle support) to build multi-hormone strategies today Prepare for CagriSema, retatrutide, and other multi-pathway agents entering the market soon Key Takeaway GLP-1 opened the doorbut the future of weight loss is multi-hormonal
For example, if morning nausea is a challenge, shift your exercise to the afternoon
Binge eating and weight loss outcomes in overweight and obese individuals with type 2 diabetes: results from the look AHEAD trial
And this nutritional depletion increases the risk of many other chronic inflammatory diseases
Providing wrap-around support for nutrition, behavior change, and mental health GLP-1 medications are approved for chronic weight management only as an adjunct to diet and exercisenot as quick fixes that cure obesity after a few doses
